Microbead Developer CyVera Becomes Subsidiary of Illumina | GenomeWeb

NEW YORK, April 12 (GenomeWeb News) - Illumina has completed its previously announced acquisition of microbead developer CyVera for $17.5 million in stock and cash, the company said yesterday.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.